Last reviewed · How we verify
NCT05558280
Qarziba for Patients in Relapsed/Refractory High-grade Osteosarcoma
Phase 2 trial testing Dinutuximab beta in Osteosarcoma in Children in 22 participants. Suspended.
15 December 2025
Quick facts
| Lead sponsor | Prof. Franca Fagioli |
|---|---|
| Phase | Phase 2 |
| Status | Suspended |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 22 |
| Start date | 30 November 2023 |
| Primary completion | 15 December 2025 |
| Estimated completion | 15 December 2026 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Dinutuximab beta — full drug profile →
Conditions studied
- Osteosarcoma in Children — all drugs for Osteosarcoma in Children →
Sponsor
Prof. Franca Fagioli
Who can join
Adults 1 to 25, any sex, with Osteosarcoma in Children. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Limited progress has been made in identifying novel targets that may be therapeutic for Osteosarcoma(OS) and there remains an urgent need for the development of new agents that are effective in improving survival. From this perspective, repurposing already proven targets in other tumors may offer new opportunities for OS in children and young adults. Anecdotal evidence of anti-GD2 therapy exists in OS from prior Phase 1 trials that included patients with OS.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Aberrant Glycosylation as Immune Therapeutic Targets for Solid Tumors.
Matsumoto Y, Ju T. · · 2023 · cited 31× · PMID 37509200 · DOI 10.3390/cancers15143536 -
Global Impact of Monoclonal Antibodies (mAbs) in Children: A Focus on Anti-GD2.
Larrosa C, Mora J, Mora J, Cheung NK. · · 2023 · cited 13× · PMID 37509390 · DOI 10.3390/cancers15143729 -
Targeted therapies in pediatric oncology: A start.
Shah N. · · 2026 · PMID 41994561 · DOI 10.1016/j.omton.2026.201146
Verify or expand the search:
- PubMed search for NCT05558280
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Dinutuximab beta
Trials testing the same drug.
- NCT06839703 — International Phase I Trial of Dinutuximab Beta With VDC/IE in GD2-Positive Ewing Sarkoma · Phase 1 · not yet recruiting
- NCT06485947 — Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma · Phase 1 · recruiting
- NCT07334301 — A Multi-Arm, Platform Trial For Relapsed Neuroblastoma · Phase 1, PHASE2 · recruiting
- NCT05754684 — Quadruple Immunotherapy for Neuroblastoma · Phase 2 · recruiting
Other Prof. Franca Fagioli trials
Trials by the same sponsor.
- NCT04802070 — Study of Adoptive Immunotherapy in Relapsed and Non-resectable Sarcomas After Multimodal Treatment. · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05558280 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Prof. Franca Fagioli
- Last refreshed: 18 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05558280.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing